Exclusive Summary

• Delivers robust head-to-head Phase 3 superiority against Rituximab, significantly increasing Complete Response (CR) （85.7% vs 77.3%）and extending long-term survival (PFS/OS), challenging the classic R-CHOP gold standard.
• Positioned as a next-generation "Bio-better" engineered via CADD, featuring defucosylation that yields 10x the ADCC activity and twice the volume of distribution for superior bulky tumor penetration.
• Exhibits an excellent safety profile strictly comparable to standard-of-care, highlighted by lower instances of specific infections and an absence of neutralizing antibodies.
• Offers expansive commercial versatility, bridging from massive oncology markets (DLBCL) to highly lucrative, underserved autoimmune indications like Membranous Nephropathy.

Asset Materials

Contact Us for Full Materials